Strategic Intelligence for Tomorrow

  1. Home
  2. Reports Store
  3. Medical Devices
Market Analysis & Forecast

In Vitro Diagnostics (IVD) Market

Report Code
CM-MD-P1-1001
Base Year
2025
Study Period
2021–2025 · 2026–2035
Geographic Scope
Global
Pages
180-220
Format
PPT / WORD / EXCEL / PDF
Published
October 2026
Delivery
48 hours
Back toHealthcare Reports

Customise your request

Need this report to answer something it does not cover? Tell us the decision you are facing and we will scope the work — or point you to a study that already answers it.

info@cortexmeridian.com+971 56 483 5090

Report Scope

Report ID / SKUCM-MD-0001
Report CodeCM-MD-P1-1001
Report TypeMarket Analysis & Forecast
Base Year2025
Historical Period2021–2025
Forecast Period2026–2035
Geographic ScopeGlobal
Global CoverageYes
Regions CoveredNorth America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Countries CoveredUS; Canada; Mexico; UK; Germany; France; Italy; Spain; Netherlands; Switzerland; China; India; Japan; South Korea; Australia; Brazil; Argentina; Saudi Arabia; UAE; South Africa (20 countries)
Market Size UnitUSD Billion
Volume UnitInstruments / Tests / Reagent Units
Report FormatPPT / WORD / EXCEL / PDF
Page Count180-220
Delivery Timeline48 hours
Sample AvailableYes
Author / AnalystCortex Meridian Medical Devices Analyst Team
Publish DateOctober 2026
Last Updated2026-10-06

Market Overview & Definition

Market Overview & Definition

The global In Vitro Diagnostics (IVD) market is valued by Cortex Meridian Research at approximately USD 107.4 billion in 2025 and is projected to reach about USD 181.7 billion by 2035, implying a CAGR of 5.4% during 2025–2035. The market is no longer expanding primarily through analyzer placements; value creation is increasingly concentrated in recurring reagents, specialty assays, software, digital pathology and integrated laboratory workflows. This matters because the installed base of analyzers in mature markets is already extensive, so vendors that can increase test menu breadth, automation throughput and clinical utility per installed instrument are better positioned to grow revenue without relying on wholesale replacement cycles.

The most important structural shift is the movement from conventional core-laboratory testing toward higher-value molecular, oncology, pathology and near-patient workflows. Screening programs, chronic-disease monitoring and companion diagnostics are increasing the frequency and complexity of testing, while laboratories are under pressure to process greater volumes with fewer skilled technicians. That is accelerating automation and consolidation around larger platform ecosystems. At the same time, reimbursement controls, China’s healthcare pricing reforms and normalized post-pandemic infectious-disease demand prevent the market from returning to the unusually high growth rates seen during COVID-19.

Competitive strategy is becoming increasingly ecosystem-led. Roche’s diagnostics portfolio expansion and proposed PathAI acquisition strengthen its ability to connect tissue diagnostics, digital pathology and oncology biomarkers. Danaher’s planned Masimo acquisition points to a different form of convergence, combining diagnostics with connected monitoring and sensor data. Abbott, Siemens Healthineers, bioMérieux, Sysmex and Thermo Fisher are also deepening specialization in high-throughput, molecular and disease-specific testing. The result is a market where share gains are likely to come from workflow ownership, recurring assay pull-through and data integration rather than from stand-alone hardware innovation alone.

Report Description

The In Vitro Diagnostics (IVD) Market covers revenue generated from the defined medical-device products, related consumables and software/services where directly attached to the device workflow. The report excludes unrelated pharmaceuticals and stand-alone healthcare services. The scope is designed for manufacturers, suppliers, distributors, hospitals, diagnostic providers, investors and strategy teams evaluating demand, technology shifts, pricing and competitive opportunity.

Overall Market Dynamics

Drivers

Rising chronic and infectious disease burden, preventive screening, decentralized testing, molecular adoption, automation and recurring reagent demand.

Restraints / Risks

Reimbursement pressure, laboratory budget constraints, regulatory complexity, commoditization in mature assays and post-pandemic normalization.

Opportunities

Multiplex testing, high-sensitivity assays, decentralized molecular testing, lab automation, companion diagnostics, APAC expansion.

Strategic themes

AI/connectivity, workflow efficiency, reimbursement, regulatory approvals, recurring consumables/service revenue, and regional access expansion.

Segmentation & Scope

Segmentation & Scope

By product: instruments, reagents, services; by technology: molecular diagnostics, immunoassay, clinical chemistry, hematology, coagulation, microbiology; by application; by test location: central lab, point-of-care, home/self testing; by end user: hospitals, laboratories, home care; by geography.

Regional & Country Outlook

Regional & Country Outlook

COUNTRY CHAPTER COVERAGE 1. US: market size & forecast; installed lab base; FDA-cleared assays; reimbursement; core-lab vs POC mix; Roche/Abbott/Danaher/Siemens positioning; molecular and pathology adoption. 2. Canada: market size & forecast; provincial lab procurement; centralized testing; public reimbursement; molecular/POC adoption; supplier landscape. 3. UK: NHS diagnostics demand; pathology-network consolidation; procurement; molecular and digital pathology adoption; reimbursement and laboratory modernization. 4. Germany: hospital/lab demand; reimbursement; automation; molecular diagnostics; pathology digitization; leading supplier penetration. 5. France: public/private lab structure; reimbursement; screening programs; molecular testing; procurement and competitive landscape. 6. Italy: regional laboratory networks; procurement; screening; POC adoption; supplier/channel structure. 7. Spain: public hospital/lab demand; decentralized testing; molecular diagnostics; reimbursement; distributor landscape. 8. Netherlands: high automation; digital pathology; precision diagnostics; centralized labs; innovative assay adoption. 9. Switzerland: premium diagnostics adoption; pharma-linked companion diagnostics; pathology and molecular testing; supplier ecosystem. 10. China: market size & forecast; localization; volume-based procurement; hospital lab expansion; domestic vs multinational suppliers; molecular testing. 11. India: private diagnostics chains; hospital labs; POC demand; price tiers; local manufacturing; infectious-disease and chronic-disease testing. 12. Japan: high-value diagnostics; aging-related screening; reimbursement; automation; molecular testing; domestic supplier competition. 13. South Korea: advanced hospital labs; molecular diagnostics; oncology testing; digital pathology; reimbursement; local innovation. 14. Australia: public/private pathology networks; reimbursement; POC adoption; molecular testing; remote-care diagnostics. 15. Brazil: private lab chains; public health testing; infectious disease; distributor economics; reimbursement/access. 16. Argentina: public/private laboratory demand; currency/pricing effects; imported devices; infectious disease and screening. 17. Saudi Arabia: Vision 2030 diagnostics expansion; hospital/lab capacity; localization; tenders; molecular and POC adoption. 18. UAE: private hospital/lab investment; premium diagnostics; centralized labs; molecular testing; distributor landscape. 19. South Africa: public/private lab split; infectious disease testing; POC access; procurement; local distribution.

Competitive Landscape & Companies Covered

Abbott; Roche Diagnostics; Danaher; Siemens Healthineers; Thermo Fisher Scientific; BD; bioMérieux; QIAGEN; QuidelOrtho; Bio-Rad Laboratories; Sysmex; Illumina

Pricing & Ecosystem

Pricing, Cost & Revenue Intelligence

Pricing intelligence benchmarks capital-system ASPs, disposable/consumable pricing, procedure-linked device pricing, service contracts, software subscriptions and regional tender dynamics where applicable. The model distinguishes capital equipment from recurring revenue and evaluates discounting, bundling, distributor margins, reimbursement sensitivity and premium technology price realization.

Value Chain & Ecosystem Analysis

The ecosystem maps component and sensor suppliers, materials vendors, device OEMs, software/AI partners, contract manufacturers, sterilization and packaging providers, distributors, hospitals/diagnostic laboratories/ASCs, clinicians, payers and regulators. The analysis identifies control points in the value chain, recurring-revenue pools, channel dependencies and partnership opportunities.

Opportunity & White-Space Analysis

A weighted opportunity model scores product segments, technologies, countries, end users and accounts using growth, market size, clinical adoption, reimbursement, competitive intensity, regulatory accessibility and margin potential. Priority white spaces include Multiplex testing, high-sensitivity assays, decentralized molecular testing, lab automation, companion diagnostics, APAC expansion.

Executive Summary

The IVD market is entering a more mature but strategically stronger phase. Cortex Meridian Research estimates the market at USD 107.4 billion in 2025, rising to approximately USD 181.7 billion by 2035 at a CAGR of 5.4%. Growth is supported less by greenfield instrument placements and more by higher-value recurring revenue from reagents, specialty assays, molecular testing, digital pathology and laboratory automation.

The strategic implication is that vendors with broad installed bases and expandable test menus have a structural advantage. Roche’s move toward AI-enabled pathology through PathAI, together with continued expansion in oncology and molecular diagnostics, illustrates how major suppliers are trying to capture more of the diagnostic workflow. Danaher’s planned Masimo acquisition suggests further convergence between diagnostic testing and connected physiological data. These moves can increase revenue per account and improve customer stickiness, but pricing pressure, reimbursement scrutiny and localization policies—especially in China—will continue to constrain growth in commoditized assay categories. The market therefore favors differentiated, high-clinical-value testing over volume-led expansion.

Key Takeaways

  • 2025 Cortex normalized estimate: USD 107.4 billion
  • 2035 normalized outlook: USD 181.7 billion
  • Normalized 2025–2035 CAGR: 5.4%
  • Key growth drivers: Rising chronic and infectious disease burden, preventive screening, decentralized testing, molecular adoption, automation and recurring reagent demand.
  • Priority opportunity areas: Multiplex testing, high-sensitivity assays, decentralized molecular testing, lab automation, companion diagnostics, APAC expansion.
  • Primary competitive set: Abbott; Roche Diagnostics; Danaher; Siemens Healthineers; Thermo Fisher Scientific; BD; bioMérieux; QIAGEN; QuidelOrtho; Bio-Rad Laboratories; Sysmex; Illumina

Table of Contents

1.EXECUTIVE SUMMARY
1.1In Vitro Diagnostics (IVD) Market snapshot
1.22025 market size and 2035 outlook
1.3Key growth opportunities
1.4Major risks and assumptions
2.MARKET DEFINITION & SCOPE
2.1Definition
2.2Inclusion/exclusion criteria
2.3Value-chain boundary
2.4Market-sizing logic
3.MARKET DYNAMICS
3.1Drivers
3.2Restraints
3.3Opportunities
3.4Technology trends
3.5Regulatory and reimbursement impact
4.MARKET SEGMENTATION & FORECAST
4.1By product/device type
4.2By technology
4.3By application/procedure
4.4By end user
4.5By geography
5.PRICING, PROCEDURE & REVENUE INTELLIGENCE
5.1ASP ranges
5.2Procedure/test utilization
5.3Capital vs recurring revenue
5.4Service/consumable economics
6.REGIONAL & COUNTRY ANALYSIS
6.1North America
6.2Europe
6.3Asia Pacific
6.4Latin America
6.5Middle East & Africa
7.COMPETITIVE LANDSCAPE
7.1Market structure
7.2Product benchmark
7.3Technology benchmark
7.4Regulatory approvals
7.5Partnerships and M&A
7.6Company profiles
8.OPPORTUNITY & COMMERCIAL INTELLIGENCE
8.1Opportunity heat map
8.2High-growth segments
8.3White-space opportunities
8.4Target customer groups
8.5Go-to-market implications
9.METHODOLOGY
9.1Primary research
9.2Secondary research
9.3Market sizing
9.4Forecasting and validation
10.APPENDIX
6.REGIONAL & COUNTRY MARKET CHAPTERS
6.1US market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.2Canada market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.3UK market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.4Germany market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.5France market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.6Italy market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.7Spain market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.8Netherlands market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.9Switzerland market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.10China market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.11India market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.12Japan market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.13South Korea market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.14Australia market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.15Brazil market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.16Argentina market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.17Saudi Arabia market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.18UAE market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.19South Africa market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities

List of Tables

  1. Global market value, 2021–2035
  2. Market by product/device type
  3. Market by technology
  4. Market by application/procedure
  5. Market by end user
  6. Market by region
  7. Country market sizing
  8. Installed base/procedure/test indicators
  9. ASP/pricing benchmark
  10. Company/product benchmark
  11. Opportunity attractiveness scoring

List of Figures

  1. Market size and CAGR outlook
  2. Segment attractiveness matrix
  3. Technology adoption curve
  4. Regional opportunity heat map
  5. Competitive positioning matrix
  6. Value-chain ecosystem map
  7. Pricing/revenue model
  8. Opportunity prioritization matrix

Research Methodology

Methodology

Cortex Meridian Research applies a triangulated market-sizing framework combining company disclosures, regulatory databases, procedure/test volumes, installed-base indicators, shipment and utilization data, hospital and laboratory purchasing patterns, reimbursement signals, product approvals, and primary research. Public market benchmarks are used only as external calibration points; Cortex values are normalized to the defined scope and forecast period. Forecasts consider technology adoption, procedure/test growth, replacement cycles, pricing, reimbursement, regulatory changes, and regional healthcare investment.

Data Sources & Validation

Company annual reports and investor materials; FDA, EMA and other regulatory databases; WHO and national health agencies; peer-reviewed clinical literature; procurement and reimbursement sources; hospital/laboratory statistics; trade and shipment indicators; company product portfolios; primary interviews; and public market benchmarks used for calibration.

FAQ — Buyer Questions

Q: What is the 2025 global In Vitro Diagnostics (IVD) market size? A: Cortex Meridian Research estimates it at approximately USD 107.4 billion.

Q: What is the 2035 market outlook? A: The normalized outlook is approximately USD 181.7 billion, based on a 5.4% CAGR assumption.

Q: What are the major growth drivers? A: Rising chronic and infectious disease burden, preventive screening, decentralized testing, molecular adoption, automation and recurring reagent demand.

Q: Which opportunities should suppliers prioritize? A: Multiplex testing, high-sensitivity assays, decentralized molecular testing, lab automation, companion diagnostics, APAC expansion.

Customization Options

Customization can include country-level sizing, procedure/test volumes, installed base, ASP benchmarking, hospital/lab account mapping, competitor benchmarking, product pipeline analysis, regulatory and reimbursement tracking, KOL mapping, distributor/channel assessment, and opportunity prioritization.

Need something this report does not cover?

Describe the decision you are facing. If a published study already answers it we will point you there; if not, we will scope the work and come back with timeline and cost.

CM-MD-0001 · CM-MD-P1-1001 · 180-220 pages · Published October 2026 · Cortex Meridian Medical Devices Analyst Team

Free Sample

Request a sample

Tell us where to send it. Samples include the table of contents, the methodology note and a representative section of the analysis.

Phone (Optional)
United Arab Emirates +971

This form is protected by reCAPTCHA. Google's Privacy Policy and Terms of Service apply.

We reply from insights@cortexmeridian.com within one working day. Your details are never shared.

Before You Buy

Enquire before buying

Ask before you commit. An analyst who knows the study answers — and if it does not cover what you need, they will say so rather than sell it to you.

Phone (Optional)
United Arab Emirates +971
What would you like to know?

This form is protected by reCAPTCHA. Google's Privacy Policy and Terms of Service apply.

We reply from insights@cortexmeridian.com within one working day. Sending this does not commit you to a purchase, and your details are never shared.

Custom Research

Customise your request

Tell us what you are trying to decide and we will come back with the scope, timeline and cost — or point you to a published report if one already answers it.

Phone (Optional)
United Arab Emirates +971
ReportIn Vitro Diagnostics (IVD) Market

This form is protected by reCAPTCHA. Google's Privacy Policy and Terms of Service apply.

We reply from insights@cortexmeridian.com within one working day. Your details are never shared.

No obligation

Schedule a consultation

Thirty minutes with a senior analyst. If published research already answers your question, we will point you to it and say so.

Phone (Optional)
United Arab Emirates +971

This form is protected by reCAPTCHA. Google's Privacy Policy and Terms of Service apply.

We reply from insights@cortexmeridian.com within one working day. Your details are never shared.